LeMaitre Vascular (NASDAQ:LMAT) Given New $93.00 Price Target at Wells Fargo & Company

LeMaitre Vascular (NASDAQ:LMAT) had its price objective reduced by Wells Fargo & Company from $97.00 to $93.00 in a research note released on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the medical instruments supplier’s stock.

A number of other equities research analysts also recently issued reports on the company. Cantor Fitzgerald increased their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Roth Capital reissued a “buy” rating and set a $108.00 target price on shares of LeMaitre Vascular in a report on Wednesday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Finally, Barrington Research reiterated an “outperform” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Stock Performance

LMAT stock traded up $1.22 during trading hours on Friday, hitting $86.82. 275,971 shares of the stock were exchanged, compared to its average volume of 182,389. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $1.97 billion, a P/E ratio of 42.15, a P/E/G ratio of 2.29 and a beta of 0.77. The company has a 50-day simple moving average of $89.58 and a two-hundred day simple moving average of $87.01.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $61.05 million for the quarter, compared to the consensus estimate of $62.18 million. During the same period in the prior year, the company posted $0.49 earnings per share. LeMaitre Vascular’s revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.48%.

Insider Buying and Selling

In related news, Director David B. Roberts sold 10,815 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the transaction, the director owned 17,976 shares of the company’s stock, valued at $1,660,802.64. This represents a 37.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John A. Roush sold 6,561 shares of the firm’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the sale, the director directly owned 2,916 shares in the company, valued at approximately $269,875.80. This trade represents a 69.23% decrease in their position. The SEC filing for this sale provides additional information. 9.50% of the stock is owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently modified their holdings of LMAT. Principal Financial Group Inc. raised its position in LeMaitre Vascular by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock worth $9,385,000 after purchasing an additional 3,248 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of LeMaitre Vascular by 9.9% in the first quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier’s stock worth $23,921,000 after acquiring an additional 25,680 shares during the period. Alps Advisors Inc. bought a new stake in LeMaitre Vascular in the first quarter valued at approximately $354,000. Mutual of America Capital Management LLC raised its holdings in LeMaitre Vascular by 6.1% during the 1st quarter. Mutual of America Capital Management LLC now owns 35,331 shares of the medical instruments supplier’s stock worth $2,964,000 after purchasing an additional 2,038 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of LeMaitre Vascular by 45.9% in the 1st quarter. Victory Capital Management Inc. now owns 79,871 shares of the medical instruments supplier’s stock worth $6,701,000 after purchasing an additional 25,133 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.